24/7 Market News Snapshot 26 September, 2025 – bioAffinity Technologies, Inc. Common Stock (NASDAQ:BIAF)
DENVER, Colo., 26 September, 2025 (www.247marketnews.com) – (NASDAQ:BIAF) are discussed in this article.
BioAffinity Technologies, Inc. (BIAF) is experiencing significant attention in the market as shares surged over 65% from yesterday’s close of $3.41, opening today at $6.18 and currently trading at $5.639. With a remarkable trading volume of 95.44 million shares, investor enthusiasm reflects a growing confidence in the company’s innovative healthcare solutions.
In conjunction with this market momentum, bioAffinity Technologies is also announcing compelling new case studies that emphasize the efficacy of its noninvasive diagnostic test, CyPath® Lung, in early lung cancer detection. The case studies reveal transformative outcomes in clinical practice, where CyPath® Lung has enabled healthcare providers to identify early-stage lung cancer and avoid unnecessary invasive procedures.
One notable case involves a 68-year-old patient, referred to as “Samuel,” in which the test successfully detected lung cancer at an early stage (Stage 1A), leading to improved treatment options and outcomes. Dr. Gordon Downie, Chief Medical Officer, remarked on the significant impact of CyPath® Lung, stating, “These findings underscore how CyPath® Lung enhances clinical decision-making.”
Another case highlighted the test’s ability to alleviate patient anxiety and prevent invasive biopsies, while a third illustrated timely radiation therapy, which avoided the need for a biopsy in a high-risk individual. This showcases the test’s critical role in personalizing patient care and refining diagnostic pathways.
Maria Zannes, President and CEO of bioAffinity Technologies, declared, “As more clinicians integrate CyPath® Lung into their practice, we witness how our technology transforms the diagnostic landscape for lung health.” With its innovative use of flow cytometry paired with artificial intelligence, CyPath® Lung stands out as a crucial tool in early cancer detection, further affirming bioAffinity Technologies’ commitment to enhancing patient care and outcomes.